Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.57 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5967321 | 0.88 | TAAR1 (0.52) | CHRNB2CHRNA4TAAR1HTR2A | |
| SCHEMBL913620 | 0.88 | TAAR1 (0.52) | CHRNB2CHRNA4TAAR1HTR2A | |
| SCHEMBL9734378 | 0.88 | TAAR1 (0.52) | CHRNB2CHRNA4TAAR1HTR2A | |
| Hydrochloric Acid SCHEMBL20746350 | 0.86 | TAAR1 (0.50) | CHRNB2CHRNA4TAAR1HTR2A | |
| SCHEMBL10422453 | 0.81 | PTGS2 (0.44) | CHRNB2CHRNA4PTGS2EPHX1 | |
| SCHEMBL9180990 | 0.81 | CHRNB2 (0.42) | CHRNB2CHRNA4PTGS2EPHX1AOC3 | |
| SCHEMBL2869497 | 0.81 | CHRNB2 (0.42) | CHRNB2CHRNA4PTGS2EPHX1AOC3 | |
| SCHEMBL13569343 | 0.78 | AOC3 (0.42) | TAAR1AOC3 | |
| SCHEMBL13569341 | 0.78 | AOC3 (0.42) | TAAR1AOC3 | |
| SCHEMBL18257696 | 0.78 | AOC3 (0.42) | TAAR1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662845-B2 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| CN-100398521-C | 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | CN | disclosed |
| US-7354940-B2 | 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| EP-1542977-B1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| US-20060276524-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB, A SWEDEN CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| CN-1688550-A | 2, 5-dioxoimidazolidin-4-yl acetamides and analogs as metalloproteinase MMP12 inhibitors | ASTRAZENECA AB (SE) | 2005-10-26 | — | — | CN | disclosed |
| EP-1542977-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | AstraZeneca AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004020415-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276524-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | MMP12, MMP13, MMP9 | CHRNB2 3961/4885CHRNA4 3991/4885AKT2 1386/4885 |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | MMP12, PDE12, MMP13 | CHRNB2 2111/4885CHRNA4 2149/4885AKT2 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.